IOME BIO
Research - Colmar, Alsace, France
IOME BIO Employees
IOME BIO Details
Cancer continues to be a leading cause of disability and early mortality worldwide. Immune checkpoint blockade with PD/L-1 therapies such as Keytruda and Opdivo can induce complete and durable clinical responses in multiple tumors, a breakthrough in cancer treatment over the last decade. However, only around 20% of patients respond and many trials have failedMany R&D programs in multiple companies are attempting to improve the clinical efficacy of PD/L-1 therapies, but no solution is yet approved. Most of these approaches target T-cells or the tumour microenvironment. Patients with healthier microbiomes respond better and therefore some companies are developing live biotherapeutics to enhance the microbiome, with initially promising clinical data.Iome-Bio offers a differentiated approach through a targeted mode of action downstream of the microbiome's action, enabling amplification of the signal with first in class monoclonal antibodies.
IOME BIO Technologies
Email Providers
Gmail
Load Balancers
Nginx
CMS
WordPress.org
Other
Mobile Friendly